Brief: Xintela Gets Patent Grant In Europe For XSTEM Stem Cell Product
March 17 (Reuters) - Xintela AB XINT.ST :
* XINTELA GETS PATENT GRANT IN EUROPE FOR XSTEM STEM CELL
PRODUCT
* PATENT IS VALID UNTIL YEAR 2038.
* EUROPEAN PATENT OFFICE (EPO) HAS TODAY APPROVED PATENT
APPLICATION FOR COMPANY'S STEM CELL PRODUCT XSTEM®
Source text for Eikon: ID:nBQN96qhWt
Further company coverage: XINT.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 587696600;))
Recent news on Xintela AB
See all newsBrief: Xintela To Raise SEK 30 Mln Via Convertible Loan From Flerie Invest
Advisory: Alerts on Xintela's phase I/IIa XSTEM results withdrawn
Brief: Xintela Q1 2026 Loss Before Tax SEK 11.8 Mln
Brief: Xintela Study Finds XSTEM Treatment Safe, Well Tolerated
Brief: Xintela Gets U.S. Patent For Xstem Treatment Of Difficult-To-Heal Wounds, Skin Defects